Autolus Therapeutics (AUTL) Shares Outstanding (Weighted Average) (2018 - 2025)

Autolus Therapeutics (AUTL) has 8 years of Shares Outstanding (Weighted Average) data on file, last reported at $266.1 million in Q2 2025.

• For the quarter ending Q2 2025, Shares Outstanding (Weighted Average) changed 0.04% year-over-year to $266.1 million; the trailing twelve-month figure through Jun 2025 stood at $266.1 million (changed 0.04% YoY), and the FY2024 full-year result was $255.2 million, up 46.69% from the prior year.
• Shares Outstanding (Weighted Average) for Q2 2025 stood at $266.1 million, roughly flat from $266.1 million in the prior quarter.
• Across five years, Shares Outstanding (Weighted Average) topped out at $90.9 billion in Q4 2021 and bottomed at $62.4 million in Q1 2021.
• The 5-year median for Shares Outstanding (Weighted Average) is $173.9 million (2023), against an average of $5.2 billion.
• The widest annual swing landed in 2021, when Shares Outstanding (Weighted Average) soared 10407834.33%; it then sank 99.9% in 2022.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $90.9 billion in 2021, then tumbled by 99.9% to $95.0 million in 2022, then jumped by 83.11% to $173.9 million in 2023, then surged by 46.69% to $255.2 million in 2024, then climbed by 4.3% to $266.1 million in 2025.
• The last three Shares Outstanding (Weighted Average) figures came in at $266.1 million (Q2 2025), $266.1 million (Q1 2025), and $255.2 million (Q4 2024), per Business Quant data.

Peer Comparison